I. Jacobson

L. Dal Maso, Z. Younossi, P. Cacoub, 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

T. Hassanein, K. Kowdley, D. Bernstein, 2013, The Lancet.

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

E. Schiff, G. Everson, K. Kowdley, 2013, The New England journal of medicine.

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

K. Reddy, T. Hassanein, D. Dieterich, 2013, The Lancet. Infectious diseases.

Thrombocytopenia associated with chronic liver disease.

M. Manns, B. Weksler, N. Afdhal, 2008, Journal of hepatology.

Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy

G. Everson, N. Terrault, D. Nelson, 2012, Hepatitis research and treatment.

Hepatitis C virus: a critical appraisal of approaches to therapy.

T. Hassanein, G. Davis, G. Everson, 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection

R. Liu, L. Chiriboga, H. Yee, 2009, Journal of viral hepatitis.

The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation.

I. Jacobson, S. Gonzalez, 2004, Cleveland Clinic journal of medicine.

Prognostic Significance of Hepatitis C Virus RNA Detection by Transcription-Mediated Amplification with Negative Polymerase Chain Reaction During Therapy with Peginterferon α and Ribavirin

I. Jacobson, S. Gonzalez, Jaydeep S. Kadam, 2007, Digestive Diseases and Sciences.

Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C.

I. Jacobson, A. Fox, Alyson N. Fox, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Brush cytology evaluation of lesions encountered during ERCP.

I. Jacobson, J. Koizumi, P. L. Scudera, 1990, Gastrointestinal endoscopy.

An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus

B. McMahon, I. Jacobson, R. Perrillo, 2022, Journal of clinical gastroenterology.

Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety

M. Russo, I. Jacobson, Robert S. Brown, 2003, American Journal of Gastroenterology.

Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.

M. Stepanova, S. Zeuzem, L. Henry, 2016, Journal of hepatology.

8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS

Tara L. Kieffer, S. Zeuzem, J. Sullivan, 2011 .

1 ATOMIC: 97% RVR FOR PSI-7977 + PEG/RBV × 12 WEEK REGIMEN IN HCV GT1: AN END TO RESPONSE-GUIDED THERAPY?

D. Bernstein, T. Hassanein, D. Nelson, 2012 .

Phase 1B, randomized, double‐blind, dose‐escalation trial of CPG 10101 in patients with chronic hepatitis C virus

B. Bacon, M. Shiffman, N. Afdhal, 2007, Hepatology.

HCV-associated mixed cryoglobulinemia B cells in + CD27 + Clonal expansion of immunoglobulin M

C. Rice, I. Jacobson, A. Talal, 2011 .

The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations.

I. Jacobson, 2016, Gastroenterology & hepatology.

HCV Council – critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape

K. Reddy, G. Everson, D. Nelson, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection.

J. Pillardy, I. Jacobson, A. Talal, 2016, The Journal of infectious diseases.

Optimal treatment with boceprevir for chronic HCV infection

I. Jacobson, Arun Jesudian, A. Jesudian, 2013 .

Telaprevir for chronic hepatitis C virus infection.

I. Jacobson, Arun Jesudian, A. Jesudian, 2013, Clinics in liver disease.

Telaprevir user's guide

I. Jacobson, Annmarie Liapakis, 2012, Liver international : official journal of the International Association for the Study of the Liver.

Telaprevir user's guide.

I. Jacobson, Annmarie Liapakis, 2011, Clinics in liver disease.

Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy.

I. Jacobson, 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Efficacy of chronic hepatitis C therapy in community-based trials.

P. Kwo, P. Marotta, I. Jacobson, 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response.

M. Manns, K. Schulman, D. Kershenobich, 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile.

E. Schiff, G. Davis, I. Jacobson, 1994, Clinical therapeutics.

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

A. Lok, K. Reddy, T. Hassanein, 2014, The New England journal of medicine.

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Brian L. Pearlman, Z. Younossi, S. Ouwerkerk-Mahadevan, 2014, The Lancet.

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

William M. Lee, K. Shianna, D. Ge, 2010, Gastroenterology.

Antisense therapy for hepatitis C virus infection.

I. Jacobson, Y. D. de Jong, 2014, Journal of hepatology.

Antisense therapy for hepatitis C virus infection Ype

I. Jacobson, P. D. Jong, 2013 .

Patient‐reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir‐containing regimens

M. Stepanova, D. Nelson, Z. Younossi, 2014, Hepatology.

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices

J. Ward, H. Razavi, D. Church, 2013, Journal of viral hepatitis.

Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis

I. Jacobson, S. Fink, 2011, Nature Reviews Gastroenterology &Hepatology.

Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016

Andrew A. Li, Z. Younossi, G. Cholankeril, 2018, Journal of viral hepatitis.

Presence of functional dendritic cells in patients chronically infected with hepatitis C virus.

C. Rice, M. Albert, R. Longman, 2004, Blood.

Optimal treatment with telaprevir for chronic HCV infection

I. Jacobson, Arun Jesudian, 2013, Liver international : official journal of the International Association for the Study of the Liver.

Update on the Diagnosis and Treatment of Hepatitis C

I. Jacobson, Arun Jesudian, A. Jesudian, 2012 .

Update on the Diagnosis a Hepatitis C

I. Jacobson, Arun Jesudian, A. Jesudian, 2012 .

Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection

Tara L. Kieffer, A. Kwong, M. Tausek, 2008 .

svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3

Brian L. Pearlman, Z. Younossi, S. Ouwerkerk-Mahadevan, 2013 .

Emerging therapeutic targets for hepatitis C virus infection.

I. Jacobson, Y. D. de Jong, Arun Jesudian, 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Impact of Hispanic or Asian Ethnicity on the Treatment Outcomes of Chronic Hepatitis C: Results From the WIN-R Trial

I. Jacobson, Robert S. Brown, B. Freilich, 2011, Journal of clinical gastroenterology.

Anti-HCV Agents in Development

I. Jacobson, K. Kulkarni, 2009 .

Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study

G. Everson, E. Verna, I. Jacobson, 2019, Clinical and translational gastroenterology.

Expert Opinion on Managing Chronic HCV Infection in Patients with Type 2 Diabetes Mellitus

M. Bondin, P. Cacoub, I. Jacobson, 2018, Antiviral therapy.

Drug profile Sofosbuvir , Velpatasvir and Voxilaprevir combination for the treatment of hepatitis C

I. Jacobson, Rebecca Voaklander, 2017 .

Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus

K. Reddy, E. Gane, D. Brainard, 2015, Hepatology.

Emerging therapies for the treatment of hepatitis C

C. Rice, S. Zeuzem, I. Jacobson, 2013, EMBO molecular medicine.

O312: How should we monitor patients after SVR?

I. Jacobson, 2014 .

Series : Host-pathogen interactions Emerging therapies for the treatment of hepatitis C

C. Rice, S. Zeuzem, I. Jacobson, 2013 .

Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.

E. Schiff, T. Hassanein, M. Yuen, 2022, Journal of hepatology.

Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).

M. Stepanova, L. Henry, D. Nelson, 2014, Journal of hepatology.

Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy.

A. Lok, K. Reddy, D. Nelson, 2019, Gastroenterology.

Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies

G. Dore, S. Zeuzem, G. Foster, 2018, Open forum infectious diseases.

Primer on Hepatitis C Virus Resistance to Direct-Acting Antiviral Treatment: A Practical Approach for the Treating Physician.

I. Weisberg, I. Jacobson, 2017, Clinics in liver disease.

L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.

H. Mo, D. Nelson, B. Doehle, 2016, The Journal of infectious diseases.

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.

V. de Lédinghen, P. Angus, K. Reddy, 2015, JAMA.

The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners

I. Jacobson, D. Gardenier, M. Olson, 2015 .

Fixed-Dose Combination TherapyWith Daclatasvir , Asunaprevir , and Beclabuvir for Noncirrhotic Patients With HCVGenotype 1 Infection

P. Angus, K. Reddy, B. Conway, 2015 .

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

M. Manns, P. Marcellin, D. Thabut, 2014, The Lancet.

Development of sofosbuvir for the treatment of hepatitis C virus infection

D. Dieterich, S. Zeuzem, D. Nelson, 2015, Annals of the New York Academy of Sciences.

HIV/Hepatitis C Virus-Coinfected Patients With Normal Alanine Aminotransferase Levels

B. Edlin, I. Jacobson, A. Talal, 2006, Journal of acquired immune deficiency syndromes.

Sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection

I. Jacobson, Saikiran M. Kilaru, 2019, Future Virology.

Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?

I. Jacobson, 2018, Gastroenterology.

Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis

M. Manns, J. Kao, J. Toyota, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct‐acting antivirals has failed

T. Hassanein, H. Mo, S. Pol, 2015, Hepatology.

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies

X. Forns, S. Zeuzem, S. Ouwerkerk-Mahadevan, 2015, Journal of viral hepatitis.

Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting

I. Jacobson, 2014 .

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

N. Parkin, H. Mo, V. Gontcharova, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

All Oral HCV Therapies of the Future

I. Jacobson, Sonal Kumar, 2013, Current Hepatitis Reports.

with hepatitis C virus Presence of functional dendritic cells in patients chronically infected

C. Rice, M. Albert, R. Longman, 2011 .

Peginterferon -2b in the treatment of hepatitis C

I. Jacobson, G. Weitzman, 2006 .

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials

Tara L. Kieffer, A. Kwong, S. Zeuzem, 2012, PloS one.

Clinical and biologic importance of F-actin autoantibodies in HCV monoinfected and HCV-HIV coinfected patients.

R. Yantiss, X. Zhou, I. Jacobson, 2010, American journal of clinical pathology.

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin

P. Marcellin, J. Albrecht, S. Zeuzem, 2012, Hepatology.

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.

Brian L. Pearlman, T. Berg, T. Asselah, 2017, Gastroenterology.

Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study

M. Manns, M. Buti, M. Sherman, 2013, Hepatology.

1366 HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN

M. Sherman, J. Albrecht, C. Niederau, 2011 .

466 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 WHEN TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR)

J. Albrecht, K. Reddy, S. Bruno, 2011 .

Predictors of Sustained Virologic Response Among Treatment-NaïVE Patients With Hepatitis C Virus Genotype 1 When Treated With Boceprevir (Boc) Plus Peginterferon Alfa-2B-Ribavirin (PR)

J. Albrecht, S. Bruno, I. Jacobson, 2011 .

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.

M. Sherman, J. Albrecht, B. Bacon, 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve european patients in the quest-1 and quest-2 phase III trials

M. Manns, P. Marcellin, G. Dore, 2014 .

Anemia management in the era of triple combination therapy for chronic HCV.

P. Kwo, K. Kowdley, I. Jacobson, 2012, Gastroenterology & hepatology.

Modern diagnosis of HBV infection

I. Jacobson, Arema A. Pereira, 2009 .

Genotype 1: Standard Treatment

I. Jacobson, Rebekah G. Gross, 2011 .

Treatment of nonresponders to standard hepatitis C therapy

I. Jacobson, M. Gambarin-Gelwan, 2006 .

O165 SIMEPREVIR PLUS SOFOSBUVIR WITH/WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL-RESPONDER/TREATMENT-NAIVE PATIENTS (COSMOS STUDY): PRIMARY ENDPOINT (SVR12) RESULTS IN PATIENTS WITH METAVIR F3–4 (COHORT 2)

Brian L. Pearlman, Z. Younossi, S. Ouwerkerk-Mahadevan, 2014 .

O7 ONCE-DAILY SIMEPREVIR (TMC435) PLUS SOFOSBUVIR (GS-7977) WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL RESPONDERS WITH METAVIR F0–2: COSMOS STUDY SUBGROUP ANALYSIS

Z. Younossi, S. Ouwerkerk-Mahadevan, M. Sulkowski, 2014 .

Hepatitis C Patients Naive , Resting Phenotype in a Subset of Accumulation of B Lymphocytes with a Rice

C. Rice, I. Jacobson, A. Bisceglie, 2003 .

Lack of effect of hepatitis B vaccine on T-cell phenotypes.

R. Rubin, I. Jacobson, J. Dienstag, 1984, The New England journal of medicine.

Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease.

V. Wong, V. de Lédinghen, M. Stepanova, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Intrahepatic levels of CXCR3‐associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C

L. Chiriboga, H. Yee, M. Markatou, 2008, Hepatology.

Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.

P. Marcellin, J. Albrecht, V. Luketic, 2014, Journal of hepatology.

Management of interferon relapsers.

I. Jacobson, 1999, The American journal of medicine.

Interferon Alpha-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT

D. Dieterich, F. Klion, M. Russo, 2004, The American Journal of Gastroenterology.

Telaprevir‐based treatment effects on hepatitis C virus in liver and blood

A. Kwong, J. Sullivan, I. Jacobson, 2014, Hepatology.

Telaprevir: hope on the horizon, getting closer.

I. Weisberg, I. Jacobson, 2009, Clinics in liver disease.

Daclatasvir plus sofosbuvir for HCV infection.

D. Nelson, M. Sulkowski, I. Jacobson, 2014, The New England journal of medicine.

1181 PHARMACOGENOMIC ANALYSIS REVEALS IMPROVED VIROLOGIC RESPONSE IN ALL IL-28B GENOTYPES IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS TREATED WITH GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN

William M. Lee, E. Schiff, A. Bisceglie, 2010 .

4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C

E. Schiff, J. Albrecht, K. Koury, 2009 .

IL28B Polymorphism, Pretreatment CXCL10, and HCV RNA Levels Predict Treatment Response in Racially Diverse HIV/HCV Coinfected and HCV Monoinfected Patients

J. Sipley, H. Rennert, I. Jacobson, 2013, Journal of acquired immune deficiency syndromes.

Pharmacogenetics of hepatitis C therapy.

I. Jacobson, Annmarie Liapakis, 2010, Pharmacogenomics.

Biliary tract obstruction in the acquired immunodeficiency syndrome.

J. Mouradian, I. Jacobson, R. Soave, 1986, Annals of internal medicine.

How to use statins in patients with chronic liver disease.

M. Russo, I. Jacobson, 2004, Cleveland Clinic journal of medicine.

Hepatitis E Virus Infection in the United States: Current Understanding of the Prevalence and Significance in the Liver Transplant Patient Population and Proposed Diagnostic and Treatment Strategies

I. Jacobson, M. Whitsett, David M. Feldman, 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Clonal expansion of immunoglobulin M (cid:1) CD27 (cid:1) B cells in HCV-associated mixed cryoglobulinemia

C. Rice, I. Jacobson, A. Talal, 2008 .

Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications

Sooah Kim, N. Theise, James S. Park, 2021, The American journal of gastroenterology.

Clinical stage molecule PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2.

A. Tewari, D. Chakravarty, S. Nair, 2020, Cell cycle.

PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2

A. Tewari, D. Chakravarty, S. Nair, 2020, bioRxiv.

Immune Modulators and Other Agents

I. Jacobson, E. Charles, 2012 .

Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis

V. Wong, K. Cusi, Z. Younossi, 2022, Journal of clinical gastroenterology.

CD56+dim and CD56+bright cell activation and apoptosis in hepatitis C virus infection

I. Jacobson, A. Talal, S. Gonzalez, 2004, Clinical and experimental immunology.

Gastrointestinal Manifestations of Diabetes

I. Jacobson, C. Frissora, 2004 .

Safety, Pharmacokinetics and Pharmacodynamics of the Oral Toll-Like Receptor 7 Agonist GS-9620 in Treatment-Naive Patients with Chronic Hepatitis C

Anh-Hoa Nguyen, L. Webster, A. Gaggar, 2015, Antiviral therapy.

Seizures During Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C: Observations From the WIN-R Trial

I. Jacobson, V. Rustgi, J. Herrera, 2011, Journal of clinical gastroenterology.

Lindau's disease and familial hyperparathyroidism.

C. Paterson, I. Jacobson, N. Hockings, 1984, Surgical neurology.

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.

E. Schiff, K. Reddy, M. Shiffman, 2016, Gastroenterology.

Amyloidosis and hyposplenism with leukocytosis and thrombocytosis.

K. Isselbacher, I. Jacobson, 1983, Annals of internal medicine.

AdvAnces in HepAtology Emerging and Novel Therapies for Hepatitis C

I. Jacobson, 2008 .

Epstein-Barr viral hepatitis: an unusual case and review of the literature.

I. Jacobson, R. Schapiro, D. L. Gang, 1984, The American journal of gastroenterology.

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

K. Kowdley, D. Bernstein, A. Tran, 2018, Kidney international reports.

2-1-2019 Ombitasvir , Paritaprevir , Ritonavir , and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

K. Kowdley, D. Bernstein, A. Tran, 2019 .

1195 Seizures during pegylated interferon and ribavirin therapy for chronic hepatitis C in the WIN-R trial

I. Jacobson, V. Rustgi, J. Herrera, 2003 .

Long‐term clearance of hepatitis C virus following interferon α‐2b or peginterferon α‐2b, alone or in combination with ribavirin

M. Manns, E. Schiff, P. Marcellin, 2013, Journal of viral hepatitis.

Epidemiology and clinical impact of hepatitis D virus (delta) infection

D. Brettler, I. Mushahwar, P. Levine, 1985, Hepatology.

A Randomized Trial of Pegylated Interferon α-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis C

E. Bini, F. Klion, M. Russo, 2005, The American Journal of Gastroenterology.

57 TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR THE TREATMENT OF HBEAG-NEGATIVE CHRONIC HEPATITIS B: WEEK 72 TDF DATA AND WEEK 24 ADEFOVIR DIPIVOXIL SWITCH DATA (STUDY 102)

P. Marcellin, A. Horban, H. Senturk, 2008 .

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.

E. Schiff, R. Sampliner, J. Albrecht, 1990, The New England journal of medicine.

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts

V. de Lédinghen, D. Thabut, X. Forns, 2022, Journal of viral hepatitis.

Anemia during treatment with peginterferon Alfa‐2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT‐2) trial

M. Manns, J. Albrecht, K. Koury, 2013, Hepatology.

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

John B. Wong, Sanjeev Arora, Uwe Siebert, 2003 .

The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.

I. Jacobson, K. Marks, 2012, Antiviral therapy.

Combination therapy for chronic hepatitis B: ready for prime time?

I. Jacobson, 2008, Journal of hepatology.

Editorial Combination therapy for chronic hepatitis B: Ready for prime time? q

I. Jacobson, 2008 .

Advancing Patient Care: Integrating New Data

M. Sherman, J. Freston, T. Wright, 2006, American Journal of Gastroenterology.

Therapeutic Options for Chronic Hepatitis B: Considerations and Controversies

I. Jacobson, 2006, The American Journal of Gastroenterology.

Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations

K. Reddy, P. Kwo, I. Jacobson, 2012, Journal of viral hepatitis.

P48 Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial

G. Dusheiko, I. Jacobson, M. Botfield, 2011, Gut.

1369 TELAPREVIR SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL

P. Marcellin, I. Jacobson, M. Botfield, 2011 .

1363 VX-222 WITH TVR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C: ZENITH STUDY INTERIM RESULTS

A. Bisceglie, D. Nelson, E. Gane, 2011 .

12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY

J. Albrecht, B. Bacon, S. Zeuzem, 2011 .

Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa

Eugene R. Schiff, Jules L. Dienstag, E. Schiff, 1989 .

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.

K. Reddy, D. Nelson, H. Vargas, 2016, Gastroenterology.

Telaprevir for previously untreated chronic hepatitis C virus infection.

Geoffrey Dusheiko, Abdul J Sankoh, Tara L. Kieffer, 2011, The New England journal of medicine.

Boceprevir for untreated chronic HCV genotype 1 infection.

M. Manns, J. Albrecht, K. Reddy, 2011, The New England journal of medicine.

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

E. Schiff, J. Albrecht, K. Koury, 2010, The Lancet.

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

G. Everson, M. Sulkowski, J. McHutchison, 2009, The New England journal of medicine.

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

T. Asselah, A. Mangia, Ching-lung Lai, 2015, The New England journal of medicine.

A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B

E. Schiff, R. Sampliner, J. Albrecht, 1990 .

Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.

A. Kwong, I. Jacobson, Ira Jacobson, 2008, Current opinion in pharmacology.

Depressive symptoms and viral clearance in patients receiving interferon-α and ribavirin for hepatitis C

C. Nemeroff, A. Manatunga, Andrew H. Miller, 2005, Brain, Behavior, and Immunity.

Sleisenger & Fordtran's Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management

I. Jacobson, Ira M. Jacobson, 1998 .

Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates

V. Wong, F. Negro, M. Stepanova, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Diagnosis and Management of Primary Biliary Cholangitis

W. Kim, P. Kwo, K. Kowdley, 2019, The American Journal of Gastroenterology.

Advances in the treatment of hepatitis C virus infection.

I. Jacobson, M. Gambarin-Gelwan, Arun Jesudian, 2012, Gastroenterology & hepatology.

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.

Stefan Zeuzem, Steven Knox, A. Mangia, 2017, Journal of hepatology.

Telaprevir for previously treated chronic HCV infection.

M. Manns, N. Terrault, S. Zeuzem, 2010, The New England journal of medicine.

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.

E. Schiff, E. Keeffe, D. Dieterich, 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The role of the woodchuck model in the treatment of hepatitis B virus infection.

B. Tennant, I. Jacobson, K. Kulkarni, 2007, Clinics in liver disease.

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States.

E. Schiff, E. Keeffe, D. Dieterich, 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop

R. Schooley, J. Pawlotsky, R. Chung, 2010, The American Journal of Gastroenterology.

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.

E. Schiff, E. Keeffe, D. Dieterich, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy

M. Washington, M. Buti, P. Marcellin, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

E. Keeffe, P. Marcellin, F. Zoulim, 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

John F. Flaherty, M. Washington, M. Buti, 2013, The Lancet.

A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update.

D. Dieterich, H. Janssen, M. Peters, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Review Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of Hcv Rna-dependent Rna Polymerase

J. Pawlotsky, I. Jacobson, I. Nájera, 2022 .

Mericitabine (RG7128), an orally administered prodrug of PSI-6130, is the most clinically advanced nucleoside analogue inhibitor of the RNA-dependent RNA poly-

J. Pawlotsky, I. Jacobson, I. Nájera, 2012 .

Slowing the progression of chronic hepatitis B

I. Jacobson, D. Purow, 2003, Postgraduate medicine.

The HCV and HIV coinfected patient: What have we learned about pathophysiology?

I. Jacobson, A. Talal, P. Canchis, 2002, Current gastroenterology reports.

Long-term follow-up of entecavir treated protocol-defined non responders in rollover study ETV-901

E. Schiff, M. Sherman, Shou-Dong Lee, 2007 .

995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC

E. Schiff, J. Albrecht, P. Kwo, 2008 .

104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS

E. Schiff, P. Marcellin, J. Albrecht, 2008 .

66 POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR R7128 WITH PEG-IFN AND RIBAVIRIN: INTERIM RESULTS OF R7128 500MG BID FOR 28 DAYS

G. Everson, D. Nelson, E. Gane, 2008 .

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients

Todd M. Allen, D. Heckerman, N. Lennon, 2008, Hepatology.

37 SUSTAINED VIROLOGIC RESPONSE (SVR) FOLLOWING RG7128 1500MG BID/PEG-IFN/RBV FOR 28 DAYS IN HCV GENOTYPE 2/3 PRIOR NON-RESPONDERS

E. Gane, J. McHutchison, I. Jacobson, 2010 .

2005 VIROLOGIC RESPONSE RATES FOLLOWING 4 WEEKS OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONICALLY-INFECTED HCV GENOTYPE-1 PATIENTS

I. Jacobson, E. Lawitz, J. Lalezari, 2010 .

1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1

I. Jacobson, E. Lawitz, J. Lalezari, 2009 .

162 Role of Interferon Response During RE-Treatment of Null Responders with Boceprevir Combination Therapy: Results of Phase II Trial

E. Schiff, P. Marcellin, J. Albrecht, 2008 .

Boceprevir Resistance-Associated Variants (Ravs) Are Observed More Frequently in HCV (GT1)-Infected Patients With Poor Response to Peginterferon Alfa-2B/Ribavirin

J. Albrecht, J. Howe, R. Ralston, 2011 .

9 BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN

J. Albrecht, J. Howe, R. Ralston, 2011 .

[786] RESULTS OF AN INTERIM ANALYSIS OF A PHASE 2 STUDY OF TELAPREVIR (VX-950) WITH PEGINTERFERON a-2a AND RIBAVIRIN IN PREVIOUSLY UNTREATED SUBJECTS WITH HEPATITIS C

G. Everson, J. McHutchison, I. Jacobson, 2007 .

Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.

S. Pol, G. Foster, E. Yoshida, 2015, Journal of hepatology.

The conundrum of relapse in STAT-C therapy: does HCV play the Red Queen or Rip Van Winkle?

R. Ralston, I. Jacobson, Margaret A. Scull, 2011, Seminars in liver disease.

[6] VALOPICITABINE (NM283), ALONE OR WITH PEG-INTERFERON, COMPARED TO PEG INTERFERON/RIBAVIRIN (PEGIFN/RBV) RETREATMENT IN PATIENTS WITH HCV-1 INFECTION AND PRIOR NON-RESPONSE TO PEGIFN/RBV: ONE-YEAR RESULTS

N. Afdhal, M. Sulkowski, I. Jacobson, 2007 .

4 PROVE1: RESULTS FROM A PHASE 2 STUDY OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH HEPATITIS C

G. Everson, J. McHutchison, I. Jacobson, 2008 .

P70 Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV Treatment-Naïve patients: final results of phase 3 ADVANCE Study

G. Dusheiko, I. Jacobson, R. Kauffman, 2011, Gut.

High Sustained Virologic Response (SVR) Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated with Boceprevir (BOC) Plus Peginterferon Alfa-2A/Ribavirin

M. Sherman, J. Albrecht, C. Niederau, 2011 .

New treatments for hepatitis C: Life cycle lessons

I. Weisberg, I. Jacobson, S. Sigal, 2007 .

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

E. Schiff, G. Davis, I. Jacobson, 1989, The New England journal of medicine.

312 Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor of HCV, given for 12 weeks

B. Bacon, M. Shiffman, R. Yu, 2003 .

Hepatitis C—A clinical review

I. Jacobson, Lionel S. D’souza, L. Wang, 2016, Journal of medical virology.

Prevalence of Chronic Hepatitis B Virus Infection in the United States.

W. Kim, R. Gish, P. Perumalswami, 2020, The American journal of gastroenterology.

Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy.

N. Terrault, I. Jacobson, 2007, Seminars in liver disease.

39 Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegifn/RBV) re-treatment in hepatitis patients with prior non-response to PEGIFN/RBV: Week 24 results

N. Afdhal, M. Sulkowski, I. Jacobson, 2006 .

Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.

C. Bodian, F. Klion, Jennifer L Jones, 2001 .

Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B

T. Therneau, W. Kim, M. Buti, 2015, Cancer.

Customizing the management of chronic hepatitis B virus infection.

R. Gish, I. Jacobson, R. Perrillo, 2007, Seminars in liver disease.

IMMUNOGENICITY OF HEPATITIS B VACCINE IN RENAL TRANSPLANT RECIPIENTS

R. Rubin, F. Delmonico, A. Cosimi, 1985, Transplantation.

Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.

H. Mo, S. Zeuzem, K. Agarwal, 2017, Journal of hepatology.

Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group.

E. Schiff, G. Davis, I. Jacobson, 1990, Journal of hepatology.

The Evolution of Clinical Trials for Hepatitis C

I. Jacobson, M. Olson, V. F. Diaz, 2019, Topics in Medicinal Chemistry.

HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment

P. Marcellin, S. Zeuzem, E. Gane, 2010 .

Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone

C. Bodian, F. Klion, Jennifer L Jones, 2001, American Journal of Gastroenterology.

Chronic hepatitis C genotype 2 and 3: are we ready for personalized medicine?

I. Jacobson, M. Gambarin-Gelwan, 2011, Journal of hepatology.

Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml)

M. Buti, P. Marcellin, A. Horban, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Halting the natural history of hepatitis B viral infection: a paradigm shift.

I. Jacobson, R. Perrillo, 2007, Seminars in liver disease.

Discovery and Development of Telaprevir

B. Govinda Rao, Ann D. Kwong, A. Kwong, 2011 .

The Future Use of Interferon in the Treatment of Hepatitis C : New Formulations , New Combinations

J. McHutchison, I. Jacobson, 2013 .

New and experimental therapies for HCV

I. Jacobson, Arema A. Pereira, 2009, Nature Reviews Gastroenterology &Hepatology.

Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.

K. Shianna, D. Ge, D. Goldstein, 2012, Journal of hepatology.

Hepatitis C therapy

I. Jacobson, 2009 .

10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB

Sanjeev Arora, M. Sherman, A. Gładysz, 2012 .

IL28B Polymorphism Predicts Virologic Response in Patients With Hepatitis C Genotype 1 Treated With Boceprevir (Boc) Combination Therapy

J. Albrecht, B. Bacon, S. Zeuzem, 2011 .

Resistance-Associated Variants in Chronic Hepatitis C Patients Treated with Protease Inhibitors

I. Jacobson, M. Gambarin-Gelwan, 2012, Current Gastroenterology Reports.

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection

J. Pawlotsky, M. Sulkowski, J. Feld, 2016, Liver international : official journal of the International Association for the Study of the Liver.

445 A PHASE 2B TRIAL COMPARING 24 TO 48 WEEKS TREATMENT WITH TEGOBUVIR (GS-9190)/PEG/RBV TO 48 WEEKS TREATMENT WITH PEG/RBV FOR CHRONIC GENOTYPE 1 HCV INFECTION

James T. Simpson, G. Foster, R. Flisiak, 2011 .

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Oliver Lenz, G. Dore, G. Foster, 2014, The Lancet.

1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY

D. Bernstein, T. Hassanein, D. Dieterich, 2011 .

Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection.

H. El‐Serag, F. Negro, G. Davis, 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

223 Prove1: Results from a Phase 2 Study of Telaprevir with Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Hepatitis C

G. Everson, J. McHutchison, I. Jacobson, 2008 .

Treatment of relapsers after combination therapy for chronic hepatitis C.

I. Jacobson, F. Ahmed, 2006, Infectious disease clinics of North America.

Treatment of relapsers after combination therapy for chronic hepatitis C.

I. Jacobson, F. Ahmed, 2004, Gastroenterology clinics of North America.

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

C. Molony, J. Albrecht, B. Bacon, 2012, Gastroenterology.

Noninvasive and Invasive Imaging of the Liver and Biliary Tract

I. Jacobson, Kevin W. Mennitt, K. Jajoo, 2011 .

804 SUSTAINED VIROLOGIC RESPONSE AFTER PEGINTERFERON ALFA-2B AND RIBAVIRIN TREATMENT PREDICTS LONG-TERM CLEARANCE OF HCV AT 5-YEAR FOLLOW-UP

M. Manns, E. Schiff, P. Marcellin, 2008 .

Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update.

D. Dieterich, H. Janssen, M. Peters, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C

A. Borczuk, M. Russo, S. Lobritto, 2002, American Journal of Gastroenterology.

Impact of weight‐based ribavirin with peginterferon alfa‐2b in african americans with hepatitis C virus genotype 1

P. Kwo, I. Jacobson, Robert S. Brown, 2007, Hepatology.

The case for simplifying and using absolute targets for viral hepatitis elimination goals

R. Malekzadeh, C. Richter, Chien-Jen Chen, 2020, Journal of viral hepatitis.

The delta hepatitis agent: "viral hepatitis, type D".

I. Jacobson, J. Dienstag, 1984, Gastroenterology.

Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B.

Linqi Zhang, M. Kreek, I. Jacobson, 2008, Addiction.

Hepatitis C Virus RNA Functionally Sequesters miR-122

A. Mele, J. Fak, R. Darnell, 2015, Cell.

Bleeding from bile duct varices: an unexpected hazard during therapeutic ERCP.

I. Jacobson, M. Tighe, 1996, Gastrointestinal endoscopy.

Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

C. Nemeroff, Andrew H. Miller, C. Raison, 2005, The Journal of clinical psychiatry.

Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.

Z. Kutalik, J. Casanova, C. Rice, 2012, Gastroenterology.

Relapsing viral hepatitis type A

I. Jacobson, J. Dienstag, B. Nath, 1985, Journal of medical virology.

Safety of ERCP during an acute MI.

I. Jacobson, M. Tighe, M. Rahmin, 1995, The American journal of gastroenterology.

"Tannenbaum" Teflon stents versus traditional polyethylene stents for treatment of malignant biliary stricture.

M. Catalano, G. Ginsberg, S. Lo, 2002, Gastrointestinal endoscopy.

ERCP for symptomatic choledocholithiasis in pregnancy.

I. Jacobson, M. Rahmin, R. Hitscherich, 1994, The American journal of gastroenterology.

Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors

B. Lonze, T. Lewis, D. Smith, 2020, Clinical transplantation.

Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset.

C. Rice, I. Jacobson, K. Ritola, 2011, Blood.

Resistance-Associated Amino Acid Variants Associated with Boceprevir plus Pegylated Interferon-α2B and Ribavirin in Patients with Chronic Hepatitis C in the Sprint-1 Trial

D. Hazuda, E. Schiff, J. Albrecht, 2013, Antiviral therapy.

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.

D. Thabut, Y. Baruch, S. Zeuzem, 2016, World journal of gastroenterology.

Accumulation of B Lymphocytes with a Naive, Resting Phenotype in a Subset of Hepatitis C Patients 1

C. Rice, I. Jacobson, J. Ni, 2003, The Journal of Immunology.

Intrahepatic CD4+ Cell Depletion in Hepatitis C Virus/HIV–Coinfected Patients

D. Dieterich, L. Chiriboga, H. Yee, 2004, Journal of acquired immune deficiency syndromes.

Anemia During Treatment With Peginterferon Alfa-2B/Ribavirin With or Without Boceprevir is Associated With Higher SVR Rates: Analysis of Previously Untreated and Previous-Treatment-Failure Patients

M. Manns, J. Albrecht, M. Burroughs, 2011 .

476 ANEMIA DURING TREATMENT WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN WITH OR WITHOUT BOCEPREVIR IS ASSOCIATED WITH HIGHER SVR RATES: ANALYSIS OF PREVIOUSLY UNTREATED AND PREVIOUS-TREATMENT-FAILURE PATIENTS

M. Manns, J. Albrecht, K. Reddy, 2011 .

Gastric and duodenal fistulas in Crohn's disease.

A. Warshaw, I. Jacobson, R. Schapiro, 1985, Gastroenterology.

Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C.

Andrew H Talal, David Butera, C. Rice, 2005, Blood.

American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.

I. Jacobson, M. Fried, Joseph K. Lim, 2017, Gastroenterology.

Impact of common risk factors of fibrosis progression in chronic hepatitis C

Z. Kutalik, D. Booth, F. Negro, 2014, Gut.

Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3

T. Asselah, M. Stepanova, L. Henry, 2018, Alimentary pharmacology & therapeutics.

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.

T. Hassanein, G. Everson, K. Kowdley, 2014, Journal of hepatology.

1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12

Sanjeev Arora, M. Sherman, A. Gładysz, 2011 .

Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.

D. D. Des Jarlais, H. Hagan, I. Jacobson, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Treatment of chronic hepatitis C with recombinant α-interferon. A multicentre randomized, controlled trial

E. Schiff, J. Albrecht, C. Meschievitz, 1990 .

Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.

P. Kwo, A. Howe, I. Jacobson, 2017, Gastroenterology.

in patients with hepatitis C Plasma chemokine levels correlate with the outcome of antiviral therapy

C. Rice, I. Jacobson, A. Bisceglie, 2013 .

55 FUTILITY RULES IN TELAPREVIR COMBINATION TREATMENT

L. Gritz, D. Bartels, I. Jacobson, 2012 .

Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.

J. Pawlotsky, J. McHutchison, K. Patel, 2004, Journal of hepatology.

Late‐onset Wilson's disease with neurological involvement in the absence of Kayser‐Fleischer rings

I. Jacobson, J. Dienstag, M. E. Ross, 1985, Annals of neurology.

Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality

M. Russo, I. Jacobson, Robert S. Brown, 2003, American Journal of Gastroenterology.

61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL

K. Kowdley, D. Nelson, D. Brainard, 2013 .

1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)

A. Lok, K. Reddy, T. Hassanein, 2013 .

Diseases of the Bile Ducts

P. Benias, I. Jacobson, D. Weine, 2018 .

Response to Article by Formann et al. (2003)

I. Jacobson, J. Mchutchison, 2004, Journal of viral hepatitis.

Boceprevir Plus Peginterferon &agr;-2b/Ribavirin in Chronic Hepatitis C Genotype 1: Impact of Baseline Viral Load on Sustained Virologic Response

M. Buti, J. Albrecht, K. Reddy, 2013, Journal of clinical gastroenterology.

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.

P. Kwo, W. Kraft, M. Sulkowski, 2013, Antiviral research.

Frequencies of Resistance-Associated Amino Acid Variants Following Combination Treatment with Boceprevir Plus PEGINTRON (PegInterferon Alfa-2b)/Ribavir in in Patients With Chronic Hepatitis C (CHC), Genotype 1 (G1)

E. Schiff, J. Albrecht, X. Tong, 2010 .

Proteome-wide Analysis and CXCL4 in Systemic Sclerosis

D. Nelson, I. Jacobson, 2014 .

Patient‐Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir

M. Stepanova, K. Kowdley, S. Zeuzem, 2017, Clinical Gastroenterology and Hepatology.

B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia

I. Jacobson, A. Talal, G. Lake‐Bakaar, 2012, Clinical and experimental immunology.

factors Associated with the Lack of Achievement of Normal Alt in Chronic Hepatitis B (chb) Patients Treated with Tenofovir Df (tdf) for up to 5 Years : 411

M. Buti, P. Marcellin, E. Gane, 2012 .

Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices

R. Basu, L. Henry, P. Puri, 2020, Alimentary pharmacology & therapeutics.

Evaluation of the pattern of liver tests and yield of cholangiography in symptomatic choledocholithiasis: a prospective study.

I. Jacobson, A. Roston, 1997, Gastrointestinal endoscopy.

Recurrent acute pancreatitis: an additional manifestation of the "wandering spleen" syndrome".

E. Kazam, I. Jacobson, P. Barie, 1996, The American journal of gastroenterology.

Superiority of Interferon-Free Regimens for Chronic Hepatitis C

S. Hunt, M. Stepanova, S. Zeuzem, 2017, Medicine.

Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

L. Gerber, M. Stepanova, L. Henry, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

New Therapies and Management Options for Hepatitis D.

Pauline R. Martin, I. Jacobson, 2023, The American journal of gastroenterology.

A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection

I. Weisberg, I. Jacobson, 2017, Expert opinion on pharmacotherapy.

Sa2073 SVR4 Results of a Once Daily Regimen of Simeprevir (TMC435) Plus Sofosbuvir (GS-7977) With or Without Ribavirin (RBV) in HCV GT 1 Null Responders

Z. Younossi, I. Jacobson, E. Lawitz, 2013 .

Quality-of-Life Tradeoffs for Hepatitis C Treatment: Do Patients and Providers Agree?

A. Mushlin, B. Schackman, Paul A Teixeira, 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination

P. Kwo, I. Jacobson, Joseph C. Ahn, 2022, Hepatology.

CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

William M. Lee, K. Shianna, D. Ge, 2010 .

Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C.

C. Rice, M. Albert, R. Longman, 2005, The Journal of infectious diseases.

Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life.

A. Mangia, K. Reddy, M. Stepanova, 2019, The American journal of gastroenterology.

SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy

R. Chung, G. Dore, E. Verna, 2017 .

ERCP : diagnostic and therapeutic applications

I. Jacobson, 1989 .

Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection.

Marianthi Markatou, Andrew H Talal, Marija Zeremski, 2009, The Journal of infectious diseases.

Peripheral CXCR 3-Associated Chemokines as Biomarkers of Fibrosis in Chronic Hepatitis C Virus Infection

Marianthi Markatou, Marija Zeremski, Andrew H. Talal, 2009 .

Managing Chronic Hepatitis C Virus Infection

I. Jacobson, 2022 .

An unusual case of acute colitis

B. Landzberg, I. Jacobson, 2000, The Lancet.

Transforming strategies to provide access to care.

B. Edlin, I. Jacobson, Edward A. Chow, 2010, The Journal of family practice.

Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients

B. Walker, S. Akira, J. Kaldor, 2011 .

Randomized Trial Comparing Dose Reduction and Growth Factor Supplementation for Management of Hematological Side Effects in HIV/Hepatitis C Virus Patients Receiving Pegylated-Interferon and Ribavirin

T. Hassanein, J. Aberg, M. Glesby, 2011, Journal of acquired immune deficiency syndromes.

WIN‐R revisited: Response to editorial

I. Jacobson, Robert S. Brown, 2008, Hepatology.

Management of hematologic side effects: Impact on compliance and efficacy

I. Jacobson, F. Ahmed, 2005 .

627 GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES

William M. Lee, G. Everson, M. Shiffman, 2009 .

1120 PSI-7977 400 MG QD SAFETY AND TOLERABILITY IN THE FIRST 450 PATIENTS TREATED FOR 12 WEEKS

Sanjeev Arora, T. Hassanein, D. Nelson, 2012 .

1044 TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON- ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY

M. Manns, N. Terrault, S. Zeuzem, 2009 .

[649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA

E. Schiff, P. Kwo, D. Bright, 2007 .

881 HIGH SVR RATES (SVR4) FOR 12-WEEK TOTAL TELAPREVIR COMBINATION THERAPY IN IL28B CC TREATMENT-NAÏVES AND PRIOR RELAPSERS WITH G1 CHRONIC HEPATITIS C: CONCISE INTERIM ANALYSIS

S. Zeuzem, D. Nelson, M. Sulkowski, 2013 .

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis

Z. Goodman, M. Stepanova, Z. Younossi, 2018, Medicine.

Comparison of Non-Tumoral Portal Vein Thrombosis Management in Cirrhotic Patients: TIPS Versus Anticoagulation Versus No Treatment

V. Prabhu, Sooah Kim, R. Hickey, 2021, Journal of clinical medicine.

O008 : Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child–pugh class B cirrhosis (C-salt part A)

G. Everson, E. Verna, I. Jacobson, 2015 .

The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis

J. Rockstroh, F. Altice, I. Jacobson, 2019, Journal of viral hepatitis.

Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to inferferon monotherapy or combination therapy, and in combination therapy relapsers

E. Bini, F. Klion, M. Russo, 2001 .

Il28B Genotype Is Not Associated with Advanced Hepatic Fibrosis in Chronic Hepatitis C Patients Enrolled in the Ideal Study

D. Goldstein, J. Fellay, J. Albrecht, 2010 .

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence

D. Nelson, J. Dillon, A. Luetkemeyer, 2021, The American journal of gastroenterology.

Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.

E. Schiff, T. Hassanein, M. Yuen, 2022, Journal of hepatology.

Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study

E. Schiff, T. Hassanein, M. Yuen, 2020, Journal of Hepatology.

Effects of the siRNA JNJ-3989 and/or the capsid assembly modulator (CAM-N) JNJ-6379 on viral markers of chronic hepatitis B (CHB): results from the REEF-1 study

M. Biermer, T. Asselah, M. Yuen, 2022, Journal of Hepatology.

Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment.

J. Pawlotsky, M. Sulkowski, J. Feld, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Genetic Variation at IFNL4 Influences Extrahepatic Interferon-Stimulated Gene Expression in Chronic HCV Patients

C. Rice, Brad R. Rosenberg, J. Schoggins, 2018, The Journal of infectious diseases.

Il28B Genetic Polymorphism Has Genome Wide Significant Associations with Serum Low Density Lipoprotein Levels and Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C (Chc)

William M. Lee, D. Ge, D. Goldstein, 2010 .

Diagnosis and Management of Hepatitis Delta Virus Infection

I. Jacobson, Paul L. Martin, K. Hu, 2023, Digestive Diseases and Sciences.

High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals

E. Schiff, K. Reddy, R. Chung, 2016 .

Long-Term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients with Chronic HCV Infection.

K. Reddy, M. Stepanova, Z. Younossi, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening of Patient-Reported Outcomes.

M. Stepanova, S. Zeuzem, S. Pol, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

740 HBSAG KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 4 YEARS

M. Buti, P. Marcellin, S. Zeuzem, 2011 .

Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C

I. Jacobson, Rebecca Voaklander, 2017, Expert review of gastroenterology & hepatology.

Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure

S. Zeuzem, H. Wedemeyer, E. Gane, 2017, Hepatology.

865 12 WEEK RESPONSE-GUIDED TREATMENT WITH THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, PLUS PEGYLATED INTERFERON/RIBAVIRIN IN TREATMENT NAÏVE GENOTYPE 1 HEPATITIS C INFECTED PATIENTS

M. Manns, P. Marcellin, E. Janczewska, 2013 .

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

M. Buti, M. Biermer, T. Asselah, 2023, The Lancet Gastroenterology & Hepatology.

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts

K. Chayama, X. Forns, S. Pol, 2021, Advances in Therapy.

Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial

G. Dore, G. Foster, S. Ouwerkerk-Mahadevan, 2013 .

PostersLate-Breaker Poster Abstracts1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL

G. Dore, G. Foster, S. Ouwerkerk-Mahadevan, 2013 .

P0644 : HCC risk scores: Application of the CU-HCC, GAG-HCC and page-B scores to chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF)

W. Kim, M. Buti, T. Berg, 2015 .

O55 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR OF HCV GENOTYPE-1 INFECTED PATIENTS WHO FAILED PRIOR THERAPY WITH PEGINTERFERON + RIBAVIRIN PLUS 1 OR 2 ADDITIONAL DIRECT-ACTING ANTIVIRAL AGENTS

T. Hassanein, S. Pol, E. Gane, 2014 .

Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.

Tara L. Kieffer, L. Gritz, D. Bartels, 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group.

E. Schiff, R. Sampliner, J. Albrecht, 1993, Gastroenterology.

Clinical predictors of response to recombinant interferon‐α treatment in patients with chronic non‐A, non‐B hepatitis (hepatitis C)

E. Schiff, J. Albrecht, G. Davis, 1994 .

Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C

I. Jacobson, M. Gambarin-Gelwan, I. Jacobson, 2008, Journal of viral hepatitis.

943f TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of The ASPIRE Trial

T. Berg, S. Zeuzem, G. Hirschfield, 2012 .

2 TMC435 IN HCV GENOTYPE 1 PATIENTS WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: FINAL SVR24 RESULTS OF THE ASPIRE TRIAL

T. Berg, S. Zeuzem, G. Hirschfield, 2012 .

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.

E. Schiff, E. Keeffe, D. Dieterich, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.

E. Schiff, E. Keeffe, D. Dieterich, 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Clinical Course of Chronic Hepatitis C in Patients with Very High Serum α-Fetoprotein Levels and Normal Hepatic Imaging

I. Jacobson, S. Gonzalez, 2005, The American Journal of Gastroenterology.

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives

S. Zeuzem, I. Jacobson, C. Welsch, 2012, Gut.

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

William M. Lee, K. Shianna, D. Ge, 2010, Gastroenterology.

Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of HCV Rna-Dependent RNA Polymerase

J. Pawlotsky, I. Jacobson, I. Nájera, 2012, Antiviral therapy.

E. Schiff, J. Albrecht, K. Koury, 2010, The Lancet.

2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)

J. Albrecht, R. Ralston, D. Pound, 2010 .

7 PSI-7977 PROTON AND ELECTRON: 100% CONCORDANCE OF SVR4 WITH SVR24 IN HCV GT1, GT2, & GT3

C. Stedman, K. Reddy, T. Hassanein, 2012 .

Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

L. Gerber, M. Stepanova, L. Henry, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients

Todd M. Allen, D. Heckerman, N. Lennon, 2008, Hepatology.

Nonalcoholic Fatty Liver Disease

M. Russo, I. Jacobson, 2002 .

Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?

I. Jacobson, 2018, Gastroenterology.

Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus

K. Reddy, E. Gane, D. Brainard, 2015, Hepatology.

LB-1 Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naïve patients with chronic HCV genotype 1 infection

Z. Younossi, S. Ouwerkerk-Mahadevan, M. Sulkowski, 2013 .

TELAPREVIR-BASED REGIMENS SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL

P. Marcellin, I. Jacobson, M. Botfield, 2011 .

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.

A. Mangia, H. Mo, G. Dore, 2017, Journal of hepatology.

LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients

E. Schiff, T. Hassanein, M. Yuen, 2019, Journal of Hepatology.

Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study.

B. Neuschwander‐Tetri, Z. Goodman, A. Sanyal, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.

S. Zeuzem, G. Hirschfield, P. Ferenci, 2014, Gastroenterology.